Recursion Pharmaceuticals Inc
NASDAQ:RXRX

Watchlist Manager
Recursion Pharmaceuticals Inc Logo
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Watchlist
Price: 4.71 USD -4.27% Market Closed
Market Cap: 2.5B USD

Recursion Pharmaceuticals Inc
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Recursion Pharmaceuticals Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
Interest Income Expense
$14.2m
CAGR 3-Years
N/A
CAGR 5-Years
66%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$2.6B
CAGR 3-Years
-5%
CAGR 5-Years
-4%
CAGR 10-Years
-7%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$694m
CAGR 3-Years
22%
CAGR 5-Years
9%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.9B
CAGR 3-Years
-30%
CAGR 5-Years
-25%
CAGR 10-Years
-18%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$476.3m
CAGR 3-Years
N/A
CAGR 5-Years
32%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$1.4B
CAGR 3-Years
N/A
CAGR 5-Years
40%
CAGR 10-Years
N/A
No Stocks Found

Recursion Pharmaceuticals Inc
Glance View

In the bustling landscape of biotech innovation, Recursion Pharmaceuticals Inc. carves a distinctive niche by marrying the worlds of biology and advanced computational techniques. Founded in 2013, this Salt Lake City-based company embarked on a mission to decode the complex tapestry of disease biology through the lens of data science and machine learning. Recursion's approach centers around its unique platform that integrates automated experimental biology with artificial intelligence to map and navigate the intricate pathways of human cellular biology. By harnessing volumes of data from high-throughput biological experiments, they aim to unearth novel insights into a multitude of diseases, particularly those that have historically evaded effective therapeutic intervention. At the heart of Recursion's business model is its ability to discover potential drug candidates rapidly and efficiently, turning traditional pharmaceutical development on its head. The company generates revenue through strategic partnerships with pharmaceutical giants, leveraging its platform to accelerate drug discovery and development processes. Collaborations often involve sharing the risk and reward of drug discovery, with Recursion providing the technological backbone to sift through vast datasets and identify promising therapeutic compounds. Additionally, Recursion invests in its pipeline of proprietary drug candidates, targeting rare genetic diseases and areas of significant unmet medical need. By aligning cutting-edge technology with the complexities of human biology, Recursion Pharmaceuticals positions itself at the forefront of transforming how diseases are understood and how new treatments are developed.

RXRX Intrinsic Value
3.73 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Recursion Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
14.2m USD

Based on the financial report for Dec 31, 2024, Recursion Pharmaceuticals Inc's Interest Income Expense amounts to 14.2m USD.

What is Recursion Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
66%

Over the last year, the Interest Income Expense growth was -25%.

Back to Top